Cochrane review finds insufficient evidence to determine if cannabinoids help or harm people with dementia
A Cochrane review of four small trials (126 participants) found very low to low certainty evidence that cannabinoids have little or no meaningful effect on cognition or behavioral symptoms in dementia.
Quick Facts
What This Study Found
Across four RCTs testing natural and synthetic THC, there was very low certainty evidence of minimal effect on cognition (1.1-point sMMSE difference) and low certainty evidence of minimal effect on behavioral symptoms (-1.97 NPI difference). Sedation was more common with nabilone.
Key Numbers
4 RCTs; 126 total participants; 3 cross-over designs; 3-14 week interventions; sMMSE difference 1.1 points (very low certainty); NPI difference -1.97 (low certainty); sedation OR 2.83 with nabilone
How They Did This
Cochrane systematic review and meta-analysis of all randomized controlled trials of cannabinoids for dementia treatment, searching multiple databases through July 2021. Four studies (126 participants) met inclusion criteria.
Why This Research Matters
Despite growing interest in cannabinoids for dementia, this rigorous Cochrane review finds the evidence base is simply too small and too uncertain to draw any meaningful conclusions about benefits or harms.
The Bigger Picture
The gap between public interest in cannabinoids for dementia and the available evidence is stark. Larger, longer, and better-designed trials are needed before any recommendations can be made.
What This Study Doesn't Tell Us
Only four small studies exist. Short treatment durations (3-14 weeks). Heterogeneous cannabinoid preparations. Most participants had Alzheimer disease, limiting generalizability to other dementias.
Questions This Raises
- ?Would longer trials show different results?
- ?Are specific cannabinoid preparations more promising than others for dementia symptoms?
- ?Should future trials focus on specific symptom domains rather than overall dementia measures?
Trust & Context
- Key Stat:
- Only 126 total participants across all four existing trials
- Evidence Grade:
- Cochrane systematic review with GRADE assessment, limited by very small evidence base
- Study Age:
- Published in 2021. The evidence base for cannabinoids in dementia remains extremely limited.
- Original Title:
- Cannabinoids for the treatment of dementia.
- Published In:
- The Cochrane database of systematic reviews, 9(9), CD012820 (2021)
- Authors:
- Bosnjak Kuharic, Dina(2), Markovic, Domagoj, Brkovic, Tonci, Jeric Kegalj, Milka, Rubic, Zana, Vuica Vukasovic, Ana, Jeroncic, Ana, Puljak, Livia
- Database ID:
- RTHC-03019
Evidence Hierarchy
Analyzes all available research on a topic using a structured method.
What do these levels mean? →Frequently Asked Questions
Can cannabinoids treat dementia?
Based on four small trials totaling 126 participants, there is insufficient evidence to determine whether cannabinoids help or harm people with dementia. Any potential effects appear too small to be clinically meaningful.
Are there risks of cannabinoids for dementia patients?
Sedation was more common with the synthetic cannabinoid nabilone compared to placebo. Otherwise, the evidence was too limited and imprecise to draw conclusions about safety.
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
Cite This Study
https://rethinkthc.com/research/RTHC-03019APA
Bosnjak Kuharic, Dina; Markovic, Domagoj; Brkovic, Tonci; Jeric Kegalj, Milka; Rubic, Zana; Vuica Vukasovic, Ana; Jeroncic, Ana; Puljak, Livia. (2021). Cannabinoids for the treatment of dementia.. The Cochrane database of systematic reviews, 9(9), CD012820. https://doi.org/10.1002/14651858.CD012820.pub2
MLA
Bosnjak Kuharic, Dina, et al. "Cannabinoids for the treatment of dementia.." The Cochrane database of systematic reviews, 2021. https://doi.org/10.1002/14651858.CD012820.pub2
RethinkTHC
RethinkTHC Research Database. "Cannabinoids for the treatment of dementia." RTHC-03019. Retrieved from https://rethinkthc.com/research/bosnjak-2021-cannabinoids-for-the-treatment
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.